IQ-AI Limited announced a recent publication in Neurosurgery Open that illustrates the clinical impact of its neuro-oncology software solutions.
The ongoing challenge with the treatment of brain tumours is that new or recurrent tumours can appear the same as treatment effect on traditional MRI images, the firm said.
READ: IQ-AI venture secures European patent for imaging tech
Today's standard of care requires either many weeks of follow-up imaging or an invasive surgical biopsy to confirm a diagnosis.
Imaging Biometrics, a subsidiary of IQ-AI Limited, has developed and validated a non-invasive, timely and quantitative imaging solution that addresses this issue, the group noted.
For the published study, IB’s platform IB Clinic was used to distinguish brain tumour tissue from treatment effect.
The results suggested that IB Clinic should be routinely used to optimise surgical guidance and pathologic diagnosis, which in turn would lead to optimised treatment management and patient outcomes.
"We are relying on FTB maps more routinely in our clinical practice as well as our weekly comprehensive multidiscipline brain tumour boards. They have proven to provide information that can help interpret MRI findings and optimize treatment for our patients," said Dr Jennifer Connelly, MD, Associate Professor of Neurology and Co-Director of the Neuro-oncology Program at Froedtert and the Medical College of Wisconsin and lead author of the paper.
The case report authors are clinicians and scientists from the Medical College of Wisconsin, which is affiliated with Froedtert Health.
For more than a decade, Froedtert Health's radiology department have used IB software for analysing MRI datasets.
Froedtert Health has recently acquired the upgraded IB Clinic - Container edition, which automatically generates quantitative rCBV and Delta T1 maps. This platform-independent processing application networks with scanners and PACS (picture archiving and communication system) and requires no manual intervention, IQ-AI said.
"There is growing interest in our automated platform," said Michael Schmainda, chief executive of IB. "The seamless integration in clinical workflows coupled with IB's quantitative and validated output is gaining the attention of large and small hospitals alike."
Shares rose 5% to 7.25p on Friday morning.